[HTML][HTML] Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma
Survival of macroscopic stage III melanoma is poor. Five-year overall survival and relapse-
free survival rates for surgery alone range from 40 to 59% and 30 to–39%, respectively. The …
free survival rates for surgery alone range from 40 to 59% and 30 to–39%, respectively. The …
Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma
ACJ van Akkooi, C Blank… - European Journal of …, 2023 - ejcancer.com
Survival of macroscopic stage III melanoma is poor. Five-year overall survival and relapse-
free survival rates for surgery alone range from 40 to 59% and 30 to–39%, respectively. The …
free survival rates for surgery alone range from 40 to 59% and 30 to–39%, respectively. The …
Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma
ACJ van Akkooi, C Blank… - European journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Survival of macroscopic stage III melanoma is poor. Five-year overall survival and relapse-
free survival rates for surgery alone range from 40 to 59% and 30 to-39%, respectively. The …
free survival rates for surgery alone range from 40 to 59% and 30 to-39%, respectively. The …
Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.
ACJ van Akkooi, C Blank… - European Journal of …, 2023 - europepmc.org
Survival of macroscopic stage III melanoma is poor. Five-year overall survival and relapse-
free survival rates for surgery alone range from 40 to 59% and 30 to-39%, respectively. The …
free survival rates for surgery alone range from 40 to 59% and 30 to-39%, respectively. The …